secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUNIC, INC. (IMUX)
CIK:        0001280776
Form:       8-K
Filed at:   2026-08-11T11:05:36+00:00
Accession:  0001193805-26-001071
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunic Q2 2026 net loss $34.1M; ENSURE top-line data expected by year-end; Ridloff joins board
--------------------------------------------------------------------------------

- Q2 2026 net loss $34.1M ($0.80/share) vs $26.8M ($2.03/share) in Q2 2025; R&D spend $25.9M.
- Cash and equivalents $155.1M at June 30, 2026; expected to fund operations into late 2027.
- Phase 3 ENSURE relapsing MS top-line data expected by end of 2026; NDA submission mid-2027 if positive.
- Elena Ridloff appointed to Board Aug 6, 2026; received options for 50,740 shares.
- Daniel Vitt resigned from Board; separation agreement provides $670K lump sum, $276K bonus, 100% equity vesting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1280776/000119380526001071/0001193805-26-001071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1280776/000119380526001071/e665684_8k-immunic.htm
  HTML page:      https://secwatch.observer/filing/0001193805-26-001071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer